Biomarin Pharmaceuticals (BMRN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
| 06-2018 | 03-2018 | 12-2017 | 09-2017 | 06-2017 | |
| Sales | 372,845 | 373,447 | 358,305 | 334,148 | 317,448 |
| Cost of Goods | 79,019 | 82,333 | 75,995 | 59,480 | 56,305 |
| Gross Profit | 293,826 | 291,114 | 282,310 | 274,668 | 261,143 |
| Operating Expenses | 319,108 | 335,819 | 225,258 | 288,875 | 300,260 |
| Operating Income | -25,263 | -44,372 | 58,047 | -13,727 | -38,812 |
| Interest Expense | 12,225 | 11,562 | 11,664 | 10,884 | 10,040 |
| Other Income | 8,311 | 5,130 | 8,215 | 3,990 | 3,306 |
| Pre-tax Income | -29,177 | -50,804 | 54,598 | -20,621 | -45,546 |
| Income Tax | -12,385 | -6,655 | 105,990 | -8,094 | -8,713 |
| Net Income Continuous | -16,792 | -44,149 | -51,392 | -12,527 | -36,833 |
| Net Income | $-16,792 | $-44,149 | $-51,392 | $-12,527 | $-36,833 |
| EPS Basic Total Ops | -0.09 | -0.25 | -0.30 | -0.07 | -0.21 |
| EPS Basic Continuous Ops | -0.09 | -0.25 | -0.29 | -0.07 | -0.21 |
| EPS Diluted Total Ops | -0.09 | -0.26 | -0.30 | -0.07 | -0.21 |
| EPS Diluted Continuous Ops | -0.09 | -0.25 | -0.29 | -0.07 | -0.21 |
| EBITDA(a) | $-5,088 | $-19,978 | $87,626 | $7,808 | $-19,060 |